clinical trial · NCT07279194
Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·phase3·recruiting·n = 825
Obesity & OverweightHDM1005 1HDM1005 2Placebo
brief summary
This is a 56-week randomized, double blinded, parallel-controlled study evaluating the efficacy andsafety of the HDM1005 in patients with obesity or overweight. Eligible participants will be screened and randomized to different dose group of HDM1005 or the placebo group at a ratio of 1:1:1 , HDM1005 or placebo will be given once weekly for 52 weeks, following by a safety follow up of 4 weeks. All participants received a lifestyle intervention that involved counselling on diet and physical activity.
started
Oct 14, 2025
primary completion
Sep 20, 2026
completion
Dec 13, 2026
last updated
Dec 12, 2025
official title
Efficacy and Safety of HDM1005 Once Weekly in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol